Glenmark Launches Zita DM: A Triple-Drug Combination for Type 2 Diabetes for just Rs 14

▴ Glenmark
Glenmark's commitment to providing affordable and effective solutions highlights its role as a leader in diabetes care. As Zita DM becomes a part of the diabetes management landscape, it holds the potential to positively impact the lives of millions of individuals suffering from this chronic�condition.

Glenmark Pharmaceuticals Limited, a leading global pharmaceutical company, has introduced a groundbreaking solution for managing type 2 diabetes in India. The newly launched Zita DM is the country's first triple-drug fixed-dose combination (FDC) that combines teneligliptin with dapagliflozin and metformin, addressing the challenges faced by diabetic patients.

India, with the second-largest diabetic population globally, has witnessed the launch of Zita DM to enhance glycemic control in individuals with type 2 diabetes. This FDC, available under the brand name Zita DM, combines the widely-used teneligliptin (20mg), dapagliflozin (10mg), and metformin SR (500mg/1000mg) in a fixed dose, requiring only once-daily consumption under a prescription.

Addressing Unmet Needs: Alok Malik, President & Business Head - India Formulations at Glenmark Pharma, highlighted the challenges faced by type 2 diabetic patients in India, including uncontrolled HbA1c levels and beta cell dysfunction affecting insulin secretion. Zita DM aims to fill this gap by offering a robust solution that not only improves glycemic control but also addresses co-morbidities such as weight gain.

Glenmark's Zita portfolio, catering to around 1.75 million type 2 diabetic patients annually in India, has been a foundation in diabetes management. With the addition of Zita DM, the comprehensive gliptin range promises to assist type 2 diabetic patients at every stage of their treatment journey.

Affordability and Accessibility: Priced at Rs. 14 per tablet, Zita DM is positioned as an affordable anti-diabetic drug. This pricing strategy is expected to lower the daily cost of therapy by 30%, making the medication more accessible to a broader population.

Market Impact and Growth: The oral anti-diabetic drugs market in India, as per IQVIA sales data for the period ending August 2023, is estimated at Rs. 12,522 crore, with an annual growth rate of 6.5%. Zita DM's entry is poised to make a significant impact on this market, offering an innovative and effective treatment option.

Glenmark's Legacy in Diabetes Care: Glenmark has a strong legacy in providing effective and affordable treatment options for patients with uncontrolled type 2 diabetes. The company has consistently introduced innovative drugs and combinations, including DPP4 inhibitors, SGLT-2 inhibitors, and various FDCs, contributing to the evolving landscape of diabetes care in India.

In conclusion, the launch of Zita DM marks a significant milestone in the management of type 2 diabetes in India. Glenmark's commitment to providing affordable and effective solutions highlights its role as a leader in diabetes care. As Zita DM becomes a part of the diabetes management landscape, it holds the potential to positively impact the lives of millions of individuals suffering from this chronic condition

Tags : #glenmark #zitadm #diabetes #diabetescare #diabtesmanagement #FDC #pharmaceutical #medicircle

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

No health without rights, says Shobha Shukla SDG-3 Lead Discussant at UN meetJuly 15, 2025
30 Minutes To Freedom, Robotic Surgery Ends 89-YO’s Swallowing NightmareJuly 15, 2025
Himalaya Wellness Champions Bhringaraja in New Anti-Hair Fall Campaign with a Tale of FriendshipJuly 15, 2025
ViiV Healthcare and Medicines Patent Pool extends voluntary licensing agreement to enable access to long-acting injectable HIV treatment July 15, 2025
Reforming global financial architecture is critical for gender equality and right to healthJuly 14, 2025
Francesco Arezzo takes office as president of Rotary InternationalJuly 14, 2025
CBM India Highlights Inclusive Eye Health at VISION 2020: The Right to Sight – INDIA 19th Annual ConferenceJuly 14, 2025
Crompton Introduces Ameo Fresh Nutri Blender, Reinforcing Its Promise of ‘Healthy Choices Made Easy’July 14, 2025
NMC Notifies Medical Institutions (Qualifications of Faculty) Regulations, 2025 to Expand Medical Education Capacity and Strengthen Faculty Availability July 14, 2025
India’s Roads, India’s Pain: Healing Beyond the HospitalJuly 14, 2025
When Weathers Go Deadly: Role Of Climate Change In Stimulating The Proliferation Of Disease-carrying VectorsJuly 14, 2025
India’s Hidden Health Emergency: Climate Pressures on WellbeingJuly 14, 2025
The Silent Urgency: Why Geriatric Health Homes Can’t Wait AnymoreJuly 14, 2025
Rewiring the Brain: How Neuroscience Apps Are Changing Stroke RecoveryJuly 14, 2025
Healing Happens at Home: How Community Care Breaks the Cycle of Repeat Hospital TripsJuly 14, 2025
The Future Is Hands-On: How AR Is Quietly Reshaping Physical TherapyJuly 14, 2025
Flying Lifelines: Why Medical Drones are Changing Supply Chains in SilenceJuly 14, 2025
The Silent Hunger Are Well Fed Indian Teens Actually MalnourishedJuly 14, 2025
Richest 1% people have enough new wealth to end annual poverty 22 times overJuly 11, 2025
Fermenta Signs Strategic MoU with NIFTEM-T to Strengthen India’s Food Fortification LandscapeJuly 11, 2025